血液學領域的共同研究及授權契約:2016年～2025年

血液學合作與許可協議為全面了解世界領先生物製藥公司正在進行的血液學交易提供了前所未有的途徑。

本報告提供了 2016 年至 2025 年 192 項血液學相關交易的詳細資訊。

此報告提供雙方宣布的交易付款條款。這些數據為付款條款和其他貿易條款提供了有用的見解。

了解潛在合作夥伴談判交易條款的彈性可以為談判過程提供重要的見解，讓您了解談判條款時會發生什麼。許多小型企業都希望有詳細的付款條款，但當涉及如何付款以及如何轉讓權利時，細節決定成敗。

本報告提供了當前協議交易和合作資料庫中記錄的自 2016 年以來宣布的合作和許可協議的綜合列表，以及可用的財務條款，以及公司及其合作夥伴向美國證券交易委員會提交的實際許可協議文件的在線副本鏈接。

報告的第一部分描述了血液學貿易和商業活動。第 1 章對報告進行了介紹，第 2 章分析了血液學領域的貿易趨勢。

第 3 章介紹了血液學領域已完成交易的財務條款以及發展階段。交易按標題金額、預付款、里程碑和特許費率列出並分類。

第 4 章回顧了血液學領域交易最活躍的 25 家生物製藥公司。對於與美國證券交易委員會 (SEC) 公開宣布的協議交易，可以透過目前協議交易和聯盟資料庫中的連結在線存取這些協議。

第 5 章全面深入地回顧了自 2016 年以來簽署和宣布的血液學交易，並提供合約文件。每個交易標題都透過網路連結連結到實際合約文件的線上版本，從而可以輕鬆、按需存取每個合約文件。

第 6 章提供了按目標列出的血液學交易的綜合目錄。

該報告還包含大量圖表和圖形，展示了自 2016 年以來血液學領域的合約趨勢和活動。

此外，還提供了按公司 A-Z 和技術類型組織的綜合貿易目錄。每個交易標題都提供了一個指向在線交易記錄的網絡鏈接，並在可用的情況下提供合同文件，從而允許根據需要輕鬆訪問每個文件。

主要優點

血液學合作與授權協議為讀者提供以下主要優勢：

• 了解 2016 年以來的合約趨勢
• 查看血液學領域的合作與許可機會
• 基準分析 - 確定交易的市場價值
• 財務條款 – 預付款、里程碑付款、特許權使用費
• 依公司 A-Z、治療重點、技術類型劃分的貿易目錄
• 大額交易金額
• 最活躍的交易者
• 確定每筆交易的資產和條款
• 查閱合約文件－洞察交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性。
• 節省數百小時的研究時間

研究範圍

• 《血液學合作與許可協議》旨在更深入地了解世界領先的生物製藥公司所達成的交易的動態和結構。

回報內容

• 生物製藥產業血液學領域的趨勢
• 合作與授權交易結構概述
• 涵蓋製藥和生物技術的血液學領域交易記錄目錄
• 主要血液學交易（各價值）
• 最活躍的血液製品許可交易撮合者

目錄

摘要整理

第1章 簡介

第2章 血液學領域的交易趨勢

• 簡介
• 多年的血液學領域的聯盟
• 各交易類型的血液學領域的聯盟
• 各業界的血液學領域的聯盟
• 各開發階段的血液學領域的聯盟
• 各技術類型的血液學領域的聯盟
• 各治療適應症的血液學領域的聯盟

第3章 血液學領域的聯盟的金融交易條件

• 簡介
• 公開血液學領域的聯盟相關財務條件
• 血液學領域的聯盟的主要價值
• 血液學領域的交易的預付款
• 血液學領域的交易的里程金
• 血液學權利金費率

第4章 主要血液學領域的交易和交易廠商

• 簡介
• 在血液學領域的聯盟最活發生的企業
• 血液學領域的最活躍的交易製造商清單
• 各價值血液學的首位交易

第5章 血液學領域的契約文件名錄

• 簡介
• 已簽約的血液學領域的聯盟交易

第6章 按治療標的血液學領域的交易

• 簡介
• 按血液學治療標的交易
• 交易名錄
• 交易目錄 - 血液學交易（按公司劃分），2016 年至 2025 年
• 交易目錄 - 按技術類型劃分的血液學交易（2016-2025 年）
• 定義交易類型
• 關於 Biopharma Research Ltd
• 當前合作夥伴關係
• 當前合約
• Current Partnering 的最新報告標題

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 192 hematology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hematology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in hematology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of hematology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in hematology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse hematology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Hematology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hematology trends and structure of deals entered into by leading biopharma companies worldwide.

Hematology Collaboration and Licensing Deals includes:

• Trends in hematology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of hematology deal records covering pharmaceutical and biotechnology
• The leading hematology deals by value
• Most active hematology licensing dealmakers

In Hematology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Hematology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

• 2.1. Introduction
• 2.2. Hematology partnering over the years
• 2.3. Hematology partnering by deal type
• 2.4. Hematology partnering by industry sector
• 2.5. Hematology partnering by stage of development
• 2.6. Hematology partnering by technology type
• 2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for hematology partnering
• 3.3. Hematology partnering headline values
• 3.4. Hematology deal upfront payments
• 3.5. Hematology deal milestone payments
• 3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in hematology partnering
• 4.3. List of most active dealmakers in hematology
• 4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

• 5.1. Introduction
• 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by hematology therapeutic target
• Deal directory
• Deal directory - Hematology deals by company A-Z 2016 to 2025
• Deal directory - Hematology deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Hematology partnering since 2016
• Figure 2: Hematology partnering by deal type since 2016
• Figure 3: Hematology partnering by industry sector since 2016
• Figure 4: Hematology partnering by stage of development since 2016
• Figure 5: Hematology partnering by technology type since 2016
• Figure 6: Hematology partnering by indication since 2016
• Figure 7: Hematology deals with a headline value
• Figure 8: Hematology deals with upfront payment values
• Figure 9: Hematology deals with milestone payment
• Figure 10: Hematology deals with royalty rates
• Figure 11: Active hematology dealmaking activity since 2016
• Figure 12: Top hematology deals by value since 2016